Detalhe da pesquisa
1.
Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study.
Clin Infect Dis
; 76(9): 1646-1654, 2023 05 03.
Artigo
Inglês
| MEDLINE | ID: mdl-36660819
2.
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.
N Engl J Med
; 382(12): 1112-1123, 2020 03 19.
Artigo
Inglês
| MEDLINE | ID: mdl-32130809
3.
Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study.
Lancet HIV
; 11(4): e222-e232, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38538161
4.
Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study.
Lancet HIV
; 11(4): e211-e221, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38538160
5.
Brief Report: Impact of COVID-19 on Cabotegravir Plus Rilpivirine Long-Acting Dosing Across 6 Ongoing Global Phase IIb and III Clinical Trials.
J Acquir Immune Defic Syndr
; 91(2): 157-161, 2022 10 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36094481
6.
Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment.
AIDS
; 36(2): 185-194, 2022 02 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34261093
7.
Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials.
J Acquir Immune Defic Syndr
; 85(4): 498-506, 2020 12 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33136751
8.
A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer's disease.
Curr Alzheimer Res
; 11(1): 47-58, 2014 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-24359500